Condensed Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 182,988	$ 47,730
Investments in marketable securities, current	50,998	220,499
Assets held for sale	20	0
Prepaid expenses and other current assets	4,777	7,136
Total current assets	238,783	275,365
Restricted cash	1,716	1,716
Investments in marketable securities, non-current	0	15,322
Property and equipment, net	12,534	22,630
Operating lease right-of-use assets	13,195	5,580
Other assets	0	1,289
Total assets	266,228	321,902
Current liabilities:
Accounts payable	3,753	2,608
Accrued compensation	1,899	3,799
Accrued research costs	30	720
Accrued expenses and other current liabilities	3,416	1,871
Operating lease liabilities, current	3,439	4,045
Total current liabilities	12,537	13,043
Operating lease liabilities, non-current	49,672	1,749
Other long- term liabilities	0	10,819
Total liabilities	62,209	25,611
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.00001 par value, 10,000,000 shares authorized as of September 30, 2023 and December 31, 2022; and no shares issued and outstanding as of September 30, 2023 and December 31, 2022	0	0
Common stock, $0.00001 par value, 300,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 57,989,273 and 58,221,760 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	1	1
Additional paid-in-capital	548,249	539,741
Accumulated other comprehensive loss	(95)	(1,048)
Accumulated deficit	(344,136)	(242,403)
Total stockholders’ equity	204,019	296,291
Total liabilities and stockholders’ equity	$ 266,228	$ 321,902